Targeted exosome Opportunities exist to promote exosome-based platforms for targeted delivery in regenerative medicine and drug delivery, aligning with EriVan Bio’s focus on biomolecule pipelines and unmet medical needs.

SMB growth With a small team and mid-range revenue, there is potential for channel partnerships, academic collaborations, and contract research or development services to scale scientific output without heavy internal headcount.

Strategic partnerships Position services around enabling technologies such as exosome isolation, characterization, and assay development to accelerate customers’ research programs in biotech and pharmaceutical sectors.

Technology stack Leverage current digital presence and cloud-based workflows to offer cloud-enabled R&D collaboration, virtual labs, and data sharing solutions tailored to small biotech startups and contract research organizations.

Funding alignment Target grant programs and early-stage funding rounds by highlighting a scalable exosome platform with regenerative medicine and targeted delivery applications, appealing to investors seeking high-impact biotech bets.